NLRP3 inflammasome in ischemic stroke: As possible therapeutic target
Inflammation is a devastating pathophysiological process during stroke, a devastating disease that is the second most common cause of death worldwide. Activation of the NOD-like receptor protein (NLRP3)-infammasome has been proposed to mediate inflammatory responses during ischemic stroke. Briefly,...
Gespeichert in:
| Veröffentlicht in: | International Journal of Stroke 2019-08, Vol.14 (6), p.574-591 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 591 |
|---|---|
| container_issue | 6 |
| container_start_page | 574 |
| container_title | International Journal of Stroke |
| container_volume | 14 |
| creator | Alishahi, Masoumeh Farzaneh, Maryam Ghaedrahmati, Farhoodeh Nejabatdoust, Armin Sarkaki, Alireza Khoshnam, Seyed Esmaeil |
| description | Inflammation is a devastating pathophysiological process during stroke, a devastating disease that is the second most common cause of death worldwide. Activation of the NOD-like receptor protein (NLRP3)-infammasome has been proposed to mediate inflammatory responses during ischemic stroke. Briefly, NLRP3 inflammasome activates caspase-1, which cleaves both pro-IL-1 and pro-IL-18 into their active pro-inflammatory cytokines that are released into the extracellular environment. Several NLRP3 inflammasome inhibitors have been promoted, including small molecules, type I interferon, micro RNAs, nitric oxide, and nuclear factor erythroid-2 related factor 2 (Nrf2), some of which are potentially efficacious clinically. This review will describe the structure and cellular signaling pathways of the NLRP3 inflammasome during ischemic stroke, and current evidence for NLRP3 inflammasome inhibitors. |
| doi_str_mv | 10.1177/1747493019841242 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2202668335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1747493019841242</sage_id><sourcerecordid>2202668335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-6a2856f92d6fbbf8d794102350d56d4fe3f01e667a40ad85b19d7293db3005733</originalsourceid><addsrcrecordid>eNp1UDtPwzAYtBCIlsLOhDKyBPyKHbNVVXlIFSAEc-TEn9uUpAm2M_DvcdXSAYnpe92d7juELgm-IUTKWyK55IphonJOKKdHaLxdpVxxdXzoGR6hM-_XGPNMMnGKRgwrvp3GaP68eHtlSb2xjW5b7bsW4pDUvlpBW1eJD677hLtk6pO-874uG0jCCpzuYQjxHrRbQjhHJ1Y3Hi72dYI-7ufvs8d08fLwNJsu0ooxGVKhaZ4Jq6gRtixtbqTiBFOWYZMJwy0wiwkIITXH2uRZSZSRVDFTMoyjdTZB1zvd3nVfA_hQtNEpNI3eQDf4glJMhcgZyyIU76CVi74d2KJ3davdd0FwsQ2v-BtepFzt1YeyBXMg_KYVAekO4PUSinU3uE389n_BH92qdQI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2202668335</pqid></control><display><type>article</type><title>NLRP3 inflammasome in ischemic stroke: As possible therapeutic target</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Alishahi, Masoumeh ; Farzaneh, Maryam ; Ghaedrahmati, Farhoodeh ; Nejabatdoust, Armin ; Sarkaki, Alireza ; Khoshnam, Seyed Esmaeil</creator><creatorcontrib>Alishahi, Masoumeh ; Farzaneh, Maryam ; Ghaedrahmati, Farhoodeh ; Nejabatdoust, Armin ; Sarkaki, Alireza ; Khoshnam, Seyed Esmaeil</creatorcontrib><description>Inflammation is a devastating pathophysiological process during stroke, a devastating disease that is the second most common cause of death worldwide. Activation of the NOD-like receptor protein (NLRP3)-infammasome has been proposed to mediate inflammatory responses during ischemic stroke. Briefly, NLRP3 inflammasome activates caspase-1, which cleaves both pro-IL-1 and pro-IL-18 into their active pro-inflammatory cytokines that are released into the extracellular environment. Several NLRP3 inflammasome inhibitors have been promoted, including small molecules, type I interferon, micro RNAs, nitric oxide, and nuclear factor erythroid-2 related factor 2 (Nrf2), some of which are potentially efficacious clinically. This review will describe the structure and cellular signaling pathways of the NLRP3 inflammasome during ischemic stroke, and current evidence for NLRP3 inflammasome inhibitors.</description><identifier>ISSN: 1747-4930</identifier><identifier>EISSN: 1747-4949</identifier><identifier>DOI: 10.1177/1747493019841242</identifier><identifier>PMID: 30940045</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; Anti-Inflammatory Agents - therapeutic use ; Humans ; Inflammasomes - drug effects ; Inflammasomes - metabolism ; Inflammation - drug therapy ; Inflammation - metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors ; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism</subject><ispartof>International Journal of Stroke, 2019-08, Vol.14 (6), p.574-591</ispartof><rights>2019 World Stroke Organization</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-6a2856f92d6fbbf8d794102350d56d4fe3f01e667a40ad85b19d7293db3005733</citedby><cites>FETCH-LOGICAL-c337t-6a2856f92d6fbbf8d794102350d56d4fe3f01e667a40ad85b19d7293db3005733</cites><orcidid>0000-0002-3834-4242</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1747493019841242$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1747493019841242$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,778,782,790,21808,27911,27913,27914,43610,43611</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30940045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alishahi, Masoumeh</creatorcontrib><creatorcontrib>Farzaneh, Maryam</creatorcontrib><creatorcontrib>Ghaedrahmati, Farhoodeh</creatorcontrib><creatorcontrib>Nejabatdoust, Armin</creatorcontrib><creatorcontrib>Sarkaki, Alireza</creatorcontrib><creatorcontrib>Khoshnam, Seyed Esmaeil</creatorcontrib><title>NLRP3 inflammasome in ischemic stroke: As possible therapeutic target</title><title>International Journal of Stroke</title><addtitle>Int J Stroke</addtitle><description>Inflammation is a devastating pathophysiological process during stroke, a devastating disease that is the second most common cause of death worldwide. Activation of the NOD-like receptor protein (NLRP3)-infammasome has been proposed to mediate inflammatory responses during ischemic stroke. Briefly, NLRP3 inflammasome activates caspase-1, which cleaves both pro-IL-1 and pro-IL-18 into their active pro-inflammatory cytokines that are released into the extracellular environment. Several NLRP3 inflammasome inhibitors have been promoted, including small molecules, type I interferon, micro RNAs, nitric oxide, and nuclear factor erythroid-2 related factor 2 (Nrf2), some of which are potentially efficacious clinically. This review will describe the structure and cellular signaling pathways of the NLRP3 inflammasome during ischemic stroke, and current evidence for NLRP3 inflammasome inhibitors.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Humans</subject><subject>Inflammasomes - drug effects</subject><subject>Inflammasomes - metabolism</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors</subject><subject>NLR Family, Pyrin Domain-Containing 3 Protein - metabolism</subject><issn>1747-4930</issn><issn>1747-4949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UDtPwzAYtBCIlsLOhDKyBPyKHbNVVXlIFSAEc-TEn9uUpAm2M_DvcdXSAYnpe92d7juELgm-IUTKWyK55IphonJOKKdHaLxdpVxxdXzoGR6hM-_XGPNMMnGKRgwrvp3GaP68eHtlSb2xjW5b7bsW4pDUvlpBW1eJD677hLtk6pO-874uG0jCCpzuYQjxHrRbQjhHJ1Y3Hi72dYI-7ufvs8d08fLwNJsu0ooxGVKhaZ4Jq6gRtixtbqTiBFOWYZMJwy0wiwkIITXH2uRZSZSRVDFTMoyjdTZB1zvd3nVfA_hQtNEpNI3eQDf4glJMhcgZyyIU76CVi74d2KJ3davdd0FwsQ2v-BtepFzt1YeyBXMg_KYVAekO4PUSinU3uE389n_BH92qdQI</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Alishahi, Masoumeh</creator><creator>Farzaneh, Maryam</creator><creator>Ghaedrahmati, Farhoodeh</creator><creator>Nejabatdoust, Armin</creator><creator>Sarkaki, Alireza</creator><creator>Khoshnam, Seyed Esmaeil</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3834-4242</orcidid></search><sort><creationdate>201908</creationdate><title>NLRP3 inflammasome in ischemic stroke: As possible therapeutic target</title><author>Alishahi, Masoumeh ; Farzaneh, Maryam ; Ghaedrahmati, Farhoodeh ; Nejabatdoust, Armin ; Sarkaki, Alireza ; Khoshnam, Seyed Esmaeil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-6a2856f92d6fbbf8d794102350d56d4fe3f01e667a40ad85b19d7293db3005733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Humans</topic><topic>Inflammasomes - drug effects</topic><topic>Inflammasomes - metabolism</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors</topic><topic>NLR Family, Pyrin Domain-Containing 3 Protein - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alishahi, Masoumeh</creatorcontrib><creatorcontrib>Farzaneh, Maryam</creatorcontrib><creatorcontrib>Ghaedrahmati, Farhoodeh</creatorcontrib><creatorcontrib>Nejabatdoust, Armin</creatorcontrib><creatorcontrib>Sarkaki, Alireza</creatorcontrib><creatorcontrib>Khoshnam, Seyed Esmaeil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International Journal of Stroke</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alishahi, Masoumeh</au><au>Farzaneh, Maryam</au><au>Ghaedrahmati, Farhoodeh</au><au>Nejabatdoust, Armin</au><au>Sarkaki, Alireza</au><au>Khoshnam, Seyed Esmaeil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NLRP3 inflammasome in ischemic stroke: As possible therapeutic target</atitle><jtitle>International Journal of Stroke</jtitle><addtitle>Int J Stroke</addtitle><date>2019-08</date><risdate>2019</risdate><volume>14</volume><issue>6</issue><spage>574</spage><epage>591</epage><pages>574-591</pages><issn>1747-4930</issn><eissn>1747-4949</eissn><abstract>Inflammation is a devastating pathophysiological process during stroke, a devastating disease that is the second most common cause of death worldwide. Activation of the NOD-like receptor protein (NLRP3)-infammasome has been proposed to mediate inflammatory responses during ischemic stroke. Briefly, NLRP3 inflammasome activates caspase-1, which cleaves both pro-IL-1 and pro-IL-18 into their active pro-inflammatory cytokines that are released into the extracellular environment. Several NLRP3 inflammasome inhibitors have been promoted, including small molecules, type I interferon, micro RNAs, nitric oxide, and nuclear factor erythroid-2 related factor 2 (Nrf2), some of which are potentially efficacious clinically. This review will describe the structure and cellular signaling pathways of the NLRP3 inflammasome during ischemic stroke, and current evidence for NLRP3 inflammasome inhibitors.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>30940045</pmid><doi>10.1177/1747493019841242</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-3834-4242</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1747-4930 |
| ispartof | International Journal of Stroke, 2019-08, Vol.14 (6), p.574-591 |
| issn | 1747-4930 1747-4949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2202668335 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Animals Anti-Inflammatory Agents - therapeutic use Humans Inflammasomes - drug effects Inflammasomes - metabolism Inflammation - drug therapy Inflammation - metabolism NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors NLR Family, Pyrin Domain-Containing 3 Protein - metabolism |
| title | NLRP3 inflammasome in ischemic stroke: As possible therapeutic target |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A29%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NLRP3%20inflammasome%20in%20ischemic%20stroke:%20As%20possible%20therapeutic%20target&rft.jtitle=International%20Journal%20of%20Stroke&rft.au=Alishahi,%20Masoumeh&rft.date=2019-08&rft.volume=14&rft.issue=6&rft.spage=574&rft.epage=591&rft.pages=574-591&rft.issn=1747-4930&rft.eissn=1747-4949&rft_id=info:doi/10.1177/1747493019841242&rft_dat=%3Cproquest_cross%3E2202668335%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2202668335&rft_id=info:pmid/30940045&rft_sage_id=10.1177_1747493019841242&rfr_iscdi=true |